AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12670086 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline Periodontal Therapeutic System (MPTS)
Number of subjects: 15
Study 12670086 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root-planing (SRP)
Number of subjects: 15
Study 12670086 — intervention group
Group type: EXPERIMENTAL
Intervention: All sites
Number of subjects: 15
Study 9818596 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized videokeratography (CVK) used for surgical planning in group A
Number of subjects: 31
Study 9818596 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B) based on refraction and keratometry alone
Number of subjects: 31
Study 9818596 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 31
Study 7655197 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral tunnel incision (5 mm) without suture (no stitch)
Number of subjects: 67
Study 7655197 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral tunnel incision (5 mm) with suture (single stitch)
Number of subjects: 67
Study 7655197 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneoscleral incision (5 mm) with suture (CS suture)
Number of subjects: 67
Study 2655184 — intervention group
Group type: EXPERIMENTAL
Intervention: PY108-068 (150 mg/day in divided doses)
Number of subjects: 19
Study 2655184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 1257172 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylobarbitone sodium 200 mg
Number of subjects: 8
Study 1257172 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide 30 mg
Number of subjects: 8
Study 1257172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30958572 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation (4 hours per day, 5 days per week for 12 weeks)
Number of subjects: 30
Study 30958572 — intervention group
Group type: COMPARATOR
Intervention: Control (no rehabilitation)
Number of subjects: 30
Study 29798123 — intervention group
Group type: EXPERIMENTAL
Intervention: Fangfenggubenkeli
Number of subjects: 100
Study 29798123 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine hydrochloride
Number of subjects: 100
Study 25314964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0
Study 25314964 — intervention group
Group type: COMPARATOR
Intervention: Placebo (from a previous PN clinical trial)
Number of subjects: 0
Study 23820196 — intervention group
Group type: EXPERIMENTAL
Intervention: Text with personalized video
Number of subjects: 0
Study 23820196 — intervention group
Group type: EXPERIMENTAL
Intervention: Text with video
Number of subjects: 0
Study 23820196 — intervention group
Group type: COMPARATOR
Intervention: Text only
Number of subjects: 0
Study 20549633 — intervention group
Group type: EXPERIMENTAL
Intervention: BDE mixture DE‐71 at doses of 0.5, 5, and 25 mg kg(‐1) body weight/day for 21 weeks
Number of subjects: 0
Study 20549633 — intervention group
Group type: EXPERIMENTAL
Intervention: BDE mixture DE‐71
Number of subjects: 0
Study 19473546 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi intervention (2 sessions/week for 8 weeks, then 1 session/week for 2 weeks)
Number of subjects: 160
Study 19473546 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (usual health care practices)
Number of subjects: 160
Study 17241416 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BTX-B) at doses ranging from 250 to 3,000 U
Number of subjects: 51
Study 17241416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 15111142 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion (n = 98) receiving autotransfused washed blood from intraoperative cell salvage and postoperative mediastinal fluid cell salvage.
Number of subjects: 200
Study 15111142 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 102) receiving stored homologous blood only after coronary artery bypass surgery.
Number of subjects: 200
Study 11583861 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 795
Study 9780640 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasterzip
Number of subjects: 20
Study 9780640 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique
Number of subjects: 20
Study 8067556 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical EMLA cream applied to the skin of the flank overlying the kidney 90 min prior to the ESWL procedure.
Number of subjects: 59
Study 8067556 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied to the skin of the flank overlying the kidney 90 min prior to the ESWL procedure.
Number of subjects: 59
Study 2898363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg day-1
Number of subjects: 2276
Study 2898363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2276
Study 30138930 — intervention group
Group type: EXPERIMENTAL
Intervention: M-bar connector
Number of subjects: 17
Study 30138930 — intervention group
Group type: EXPERIMENTAL
Intervention: AP-bar connector
Number of subjects: 17
Study 30138930 — intervention group
Group type: COMPARATOR
Intervention: No connector
Number of subjects: 17
Study 27402556 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Alagebrium
Number of subjects: 62
Study 27402556 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Placebo
Number of subjects: 62
Study 27402556 — intervention group
Group type: COMPARATOR
Intervention: Sedentary + Alagebrium
Number of subjects: 62
Study 27402556 — intervention group
Group type: COMPARATOR
Intervention: Sedentary + Placebo
Number of subjects: 62
Study 25262259 — intervention group
Group type: EXPERIMENTAL
Intervention: PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg)
Number of subjects: 1049
Study 25262259 — intervention group
Group type: COMPARATOR
Intervention: EC-ASA 325 mg
Number of subjects: 1049
Study 25262259 — intervention group
Group type: EXPERIMENTAL
Intervention: PA32540
Number of subjects: 1049
Study 25262259 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1049
Study 22835615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal CPAP (8-10 cmH(2)O)
Number of subjects: 25
Study 22835615 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (0-2 cmH(2)O)
Number of subjects: 25
Study 22835615 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CPAP vs Sham
Number of subjects: 25
Study 19945509 — intervention group
Group type: EXPERIMENTAL
Intervention: bromazepam 3mg
Number of subjects: 39
Study 19945509 — intervention group
Group type: EXPERIMENTAL
Intervention: bromazepam 6mg
Number of subjects: 39
Study 19945509 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study 18284414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake decreased by 25% for 4 days
Number of subjects: 24
Study 18284414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake increased by 25%
Number of subjects: 24
Study 18284414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake increased by 50%
Number of subjects: 24
Study 18284414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake decreased by 25%
Number of subjects: 24
Study 15937581 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria tents
Number of subjects: 70
Study 15937581 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol 200 microg
Number of subjects: 70
Study 12865387 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt with added probiotic microorganisms
Number of subjects: 24
Study 12865387 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 24
Study 10700778 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO2 1.0)
Number of subjects: 10
Study 10700778 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (FIO2 0.21)
Number of subjects: 10
Study 10700778 — intervention group
Group type: COMPARATOR
Intervention: Hypocapnia (FIO2 0.21)
Number of subjects: 10
Study 8881845 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5-10 mg once daily
Number of subjects: 128
Study 8881845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 1942470 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (1.34 micrograms/kg per d)
Number of subjects: 0
Study 1942470 — intervention group
Group type: COMPARATOR
Intervention: Control group (no selenium supplementation)
Number of subjects: 0
Study 7199331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 microgram kg‐1
Number of subjects: 99
Study 7199331 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 99
Study 7199331 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 99
Study 7199331 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam, fentanyl, and nitrous oxide
Number of subjects: 99
Study 30807426 — intervention group
Group type: EXPERIMENTAL
Intervention: UI‐ELM intervention (35 students)
Number of subjects: 83
Study 30807426 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group, 20 students)
Number of subjects: 83
Study 30807426 — intervention group
Group type: COMPARATOR
Intervention: UroGyn exposure (28 students)
Number of subjects: 83
Study 27314596 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel®
Number of subjects: 60
Study 27314596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu® AuraOnce (AO)TM
Number of subjects: 60
Study 27821836 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (Group G)
Number of subjects: 177
Study 27821836 — intervention group
Group type: EXPERIMENTAL
Intervention: GEA with 1.0% lidocaine (Group L1.0)
Number of subjects: 177
Study 27821836 — intervention group
Group type: EXPERIMENTAL
Intervention: GEA with 1.5% lidocaine (Group L1.5)
Number of subjects: 177
Study 24102416 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (20 mg orally each day)
Number of subjects: 63
Study 24102416 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg orally each day)
Number of subjects: 63
Study 24102416 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg orally each day)
Number of subjects: 63
Study 24102416 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregate pre‐eclampsia
Number of subjects: 63
Study 23610075 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg epicatechin from apple extract
Number of subjects: 0
Study 23610075 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 mg epicatechin from apple extract
Number of subjects: 0
Study 23610075 — intervention group
Group type: COMPARATOR
Intervention: 70 mg epicatechin from apple puree
Number of subjects: 0
Study 23610075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20831709 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate supplementation (200,000 IU megadose)
Number of subjects: 73
Study 20831709 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 73
Study 17552881 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells from untreated patients
Number of subjects: 5
Study 17552881 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells from treated patients
Number of subjects: 5
Study 17552881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dendritic cells with tetanus toxoid in untreated patients
Number of subjects: 5
Study 17552881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dendritic cells with tetanus toxoid in treated patients
Number of subjects: 5
Study 17552881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dendritic cells (both treated and untreated patients)
Number of subjects: 5
Study 17552881 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 lymphocyte proliferation in treated and untreated patients
Number of subjects: 5
Study 15919731 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BRS in IBS patients (7.9 +/- 5.4 ms/mmHg)
Number of subjects: 123
Study 15919731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild visceral stimulation (15 mmHg)
Number of subjects: 123
Study 15919731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense visceral stimulation (35 mmHg)
Number of subjects: 123
Study 14526208 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention program
Number of subjects: 326
Study 14526208 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 326
Study 14526208 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention program and Standard care (control group)
Number of subjects: 326
Study 10390384 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 33
Study 8893678 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg of estrone sulfate (E1S)
Number of subjects: 21
Study 8893678 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of 17 alpha-dihydroequilin sulfate
Number of subjects: 21
Study 8893678 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of E1S and 17 alpha-dihydroequilin sulfate
Number of subjects: 21
Study 8393589 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Number of subjects: 0
Study 8393589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study 8393589 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-containing regimen
Number of subjects: 0
Study 3522832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 107
Study 3522832 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin plus chloramphenicol
Number of subjects: 107
Study 30141228 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici (1 × 10^9 colony-forming units each strain)
Number of subjects: 209
Study 30141228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 30141228 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici
Number of subjects: 209
Study 27977392 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 823
Study 27977392 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 823
Study 27977392 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 823
Study 27977392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 823
Study 25496294 — intervention group
Group type: EXPERIMENTAL
Intervention: BVM biofeedback
Number of subjects: 0
Study 25496294 — intervention group
Group type: COMPARATOR
Intervention: Standard HD
Number of subjects: 0
Study 24114515 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid medial approach (HMA)
Number of subjects: 99
Study 24114515 — intervention group
Group type: COMPARATOR
Intervention: Completely medial approach (CMA)
Number of subjects: 99
Study 22413151 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 0
Study 22413151 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0
Study 19388617 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking compression plate
Number of subjects: 64
Study 19388617 — intervention group
Group type: COMPARATOR
Intervention: Nonlocking plate
Number of subjects: 64
Study 17156397 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Number of subjects: 15
Study 17156397 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 15
Study 15854088 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy (PP)
Number of subjects: 100
Study 15854088 — intervention group
Group type: COMPARATOR
Intervention: Control group (no posterior pericardiotomy)
Number of subjects: 100
Study 11975938 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln (beta-hydroxy-beta-methylbutyrate 3 g/d, L-arginine 14 g/d, L-glutamine 14 g/d)
Number of subjects: 32
Study 11975938 — intervention group
Group type: COMPARATOR
Intervention: Control (isonitrogenous mixture of nonessential amino acids)
Number of subjects: 32
Study 11975938 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln
Number of subjects: 32
Study 11975938 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 9873962 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms/kg rocuronium
Number of subjects: 85
Study 9873962 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 micrograms/kg rocuronium
Number of subjects: 85
Study 8712393 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.2% isoflurane and 30% nitrous oxide in oxygen
Number of subjects: 10
Study 8712393 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.4% isoflurane and 30% nitrous oxide in oxygen
Number of subjects: 10
Study 8712393 — intervention group
Group type: COMPARATOR
Intervention: 0.2% isoflurane in oxygen
Number of subjects: 10
Study 8712393 — intervention group
Group type: COMPARATOR
Intervention: 0.4% isoflurane in oxygen
Number of subjects: 10
Study 8712393 — intervention group
Group type: COMPARATOR
Intervention: 30% nitrous oxide in oxygen
Number of subjects: 10
Study 8712393 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen-placebo
Number of subjects: 10
Study 2066595 — intervention group
Group type: EXPERIMENTAL
Intervention: HR 0.5 g group (0.5 g X 2/day of CPR)
Number of subjects: 121
Study 2066595 — intervention group
Group type: EXPERIMENTAL
Intervention: HR 1.0 g group (1.0 g X 2/day of CPR)
Number of subjects: 121
Study 2066595 — intervention group
Group type: COMPARATOR
Intervention: CAZ group (1.0 g X 2/day of CAZ)
Number of subjects: 121
Study 6843050 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (Phyllotemp ret., 2 X 225 mg)
Number of subjects: 13
Study 6843050 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg body weight, i.v.)
Number of subjects: 13
Study 6843050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31027457 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 413
Study 31027457 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Number of subjects: 413
Study 31027457 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 413
Study 29900704 — intervention group
Group type: EXPERIMENTAL
Intervention: Pixel-based second harmonic generation (SHG) polarization microscopy analyses
Number of subjects: 0
Study 26739339 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cognitive behavioral program (7 sessions: 3 home visits and 4 telephone contacts)
Number of subjects: 389
Study 26739339 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cognitive behavioral program
Number of subjects: 389
Study 26739339 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 389
Study 24858870 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Activation Intervention
Number of subjects: 0
Study 24858870 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 22067410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg three times a day)
Number of subjects: 32
Study 22067410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19104200 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 148) received a 1-hour training on information technology use, a CD-ROM on cancer, and a list of reputable cancer-related websites.
Number of subjects: 250
Study 19104200 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 102) received usual care.
Number of subjects: 250
Study 19104200 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (part of the intervention group)
Number of subjects: 250
Study 17584826 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel administration
Number of subjects: 84
Study 17584826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative docetaxel doses and number of chemotherapy cycles
Number of subjects: 84
Study 15516162 — intervention group
Group type: EXPERIMENTAL
Intervention: Early lip repair at median age 4 days (IQR = 4)
Number of subjects: 0
Study 15516162 — intervention group
Group type: COMPARATOR
Intervention: Late lip repair at median age 104 days (IQR = 57)
Number of subjects: 0
Study 15516162 — intervention group
Group type: COMPARATOR
Intervention: Normal comparison infants
Number of subjects: 0
Study 12207094 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (2 g NaCl/day)
Number of subjects: 75
Study 12207094 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (20-23 g)
Number of subjects: 75
Study 12207094 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (2 g NaCl/day) after high-salt diet
Number of subjects: 75
Study 12207094 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ADMA level >/=3 microM
Number of subjects: 75
Study 12207094 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of dialysis treatment
Number of subjects: 75
Study 9815203 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI‐493 (15 mg/kg intravenous infusion)
Number of subjects: 35
Study 9815203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 9815203 — intervention group
Group type: COMPARATOR
Intervention: MEDI‐493 and Placebo
Number of subjects: 35
Study 7660443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 115
Study 7660443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine/sulfadoxine/pyrimethamine
Number of subjects: 115
Study 7660443 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 115
Study 1892302 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-571 (1,500, 86, or 28 mg)
Number of subjects: 12
Study 1892302 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-571 (28 mg)
Number of subjects: 12
Study 1892302 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-571 (277 mg)
Number of subjects: 12
Study 1892302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6684935 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemetizide 1, 5, 10, 20, 50 mg
Number of subjects: 0